Sanofi says it may look at next gen­er­a­tion of weight loss drugs: #JPM24

SAN FRAN­CIS­CO — Sanofi might not be done with the weight loss space af­ter all.

Af­ter its own GLP-1 drug failed a mid-stage tri­al al­most half a decade ago, the French drug­mak­er missed out on what has be­come the biggest new drug cat­e­go­ry of the decade. On Wednes­day at the JP Mor­gan Health­care Con­fer­ence, top ex­ec­u­tives at the com­pa­ny said they could look at po­ten­tial next-gen­er­a­tion prod­ucts in the years to come that could be more tar­get­ed or have bet­ter side ef­fects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER